Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
Clinical Pharmacology & Therapeutics2017Vol. 102(3), pp. 397–404
Citations Over TimeTop 1% of 2017 papers
JA Johnson, KE Caudle, Li Gong, Michelle Whirl‐Carrillo, Catherine M. Stein, Stuart A. Scott, MT Lee, Brian F. Gage, SE Kimmel, Minoli A. Perera, JL Anderson, Munir Pirmohamed, Teri E. Klein, NA Limdi, Larisa H. Cavallari, Mia Wadelius
Abstract
This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.
Related Papers
- → VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children(2011)107 cited
- → Role of Warfarin Pharmacogenetic Testing in Clinical Practice(2010)60 cited
- Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.(2011)
- → Clinical Effect of CYP2C9*5/*6 Genotype on a Patient’s Warfarin Dose Requirement(2017)7 cited
- → Hyper-responsiveness to Warfarin in A Young Patient with The VKORC1 -1639GA/CYP2C9*1*46 Genotype: A Case Report(2022)